EHA 2021 | Challenges and next steps for CAR-T in B-cell lymphomas
Claire Roddie, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the biggest challenges and next steps for chimeric antigen receptor T-cell (CAR-T) therapy for patients with B-cell lymphomas. Dr Roddie talks on challenges around manufacturing and the long wait time associated with the manufacturing period, commenting on studies which aim to manufacture CAR T-cells within 24 hours and the potential of developing and using allogeneic CAR-T cells. Dr Roddie also highlights the poor responses of some patients, the need to develop a deeper understanding on the causes of non-response to CAR-T, and the need for improved bridging strategies. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
